
Global Biopharmaceutical and Bio-CDMO Competitive Landscape Professional Research Report 2025
Description
Global Biopharmaceutical and Bio-CDMO Competitive Landscape Professional Research Report 2025
Research Summary
Biopharmaceuticals are medical drugs produced using living organisms or biological systems, as opposed to traditional chemically synthesized pharmaceuticals. These drugs include a wide range of products such as monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, which are used to treat various diseases, including cancer, autoimmune disorders, and infectious diseases. Biopharmaceuticals often require complex manufacturing processes involving cell cultures or fermentation. A Bio-CDMO (Biopharmaceutical Contract Development and Manufacturing Organization) is a specialized service provider that assists biopharmaceutical companies in developing and manufacturing these complex biologic drugs. Bio-CDMOs offer a range of services, including process development, scale-up, clinical and commercial production, and regulatory support, helping clients bring biopharmaceutical products to market more efficiently and cost-effectively. These organizations provide expertise in areas such as biologic formulation, purification, and quality control, ensuring that biopharmaceuticals are produced at high quality and in compliance with regulatory standards, often for clients who lack the resources or facilities to handle production in-house.
According to DIResearch's in-depth investigation and research, the global Biopharmaceutical and Bio-CDMO market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Biopharmaceutical and Bio-CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Biopharmaceutical and Bio-CDMO. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biopharmaceutical and Bio-CDMO market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biopharmaceutical and Bio-CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biopharmaceutical and Bio-CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Biopharmaceutical and Bio-CDMO Include:
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Biopharmaceutical and Bio-CDMO Product Segment Include:
Cell and Gene Therapies
Antibodies
Vaccines
Others
Biopharmaceutical and Bio-CDMO Product Application Include:
SMBs
Large Companies
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Biopharmaceutical and Bio-CDMO Industry PESTEL Analysis
Chapter 3: Global Biopharmaceutical and Bio-CDMO Industry Porter’s Five Forces Analysis
Chapter 4: Global Biopharmaceutical and Bio-CDMO Major Regional Market Size and Forecast Analysis
Chapter 5: Global Biopharmaceutical and Bio-CDMO Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Biopharmaceutical and Bio-CDMO Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Biopharmaceutical and Bio-CDMO Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Biopharmaceutical and Bio-CDMO Product by Type
- 1.2.1 Cell and Gene Therapies
- 1.2.2 Antibodies
- 1.2.3 Vaccines
- 1.2.4 Others
- 1.3 Biopharmaceutical and Bio-CDMO Product by Application
- 1.3.1 SMBs
- 1.3.2 Large Companies
- 1.4 Global Biopharmaceutical and Bio-CDMO Market Size Analysis (2020-2032)
- 1.5 Biopharmaceutical and Bio-CDMO Market Development Status and Trends
- 1.5.1 Biopharmaceutical and Bio-CDMO Industry Development Status Analysis
- 1.5.2 Biopharmaceutical and Bio-CDMO Industry Development Trends Analysis
- 2 Biopharmaceutical and Bio-CDMO Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Biopharmaceutical and Bio-CDMO Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Biopharmaceutical and Bio-CDMO Market Analysis by Regions
- 4.1 Biopharmaceutical and Bio-CDMO Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Biopharmaceutical and Bio-CDMO Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Biopharmaceutical and Bio-CDMO Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Biopharmaceutical and Bio-CDMO Revenue Forecast by Region (2026-2032)
- 5 Global Biopharmaceutical and Bio-CDMO Market Size by Type and Application
- 5.1 Global Biopharmaceutical and Bio-CDMO Market Size by Type (2020-2032)
- 5.2 Global Biopharmaceutical and Bio-CDMO Market Size by Application (2020-2032)
- 6 North America
- 6.1 North America Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Biopharmaceutical and Bio-CDMO Market Size by Type
- 6.4 North America Biopharmaceutical and Bio-CDMO Market Size by Application
- 6.5 North America Biopharmaceutical and Bio-CDMO Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Biopharmaceutical and Bio-CDMO Market Size by Type
- 7.4 Europe Biopharmaceutical and Bio-CDMO Market Size by Application
- 7.5 Europe Biopharmaceutical and Bio-CDMO Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Biopharmaceutical and Bio-CDMO Market Size by Type
- 8.4 China Biopharmaceutical and Bio-CDMO Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Biopharmaceutical and Bio-CDMO Market Size by Type
- 9.4 APAC (excl. China) Biopharmaceutical and Bio-CDMO Market Size by Application
- 9.5 APAC (excl. China) Biopharmaceutical and Bio-CDMO Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Biopharmaceutical and Bio-CDMO Market Size by Type
- 10.4 Latin America Biopharmaceutical and Bio-CDMO Market Size by Application
- 10.5 Latin America Biopharmaceutical and Bio-CDMO Market Size by Country
- 10.5.1 Mexico
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Type
- 11.4 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Application
- 11.5 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Biopharmaceutical and Bio-CDMO Market Revenue by Key Manufacturers (2021-2025)
- 12.2 Biopharmaceutical and Bio-CDMO Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Biopharmaceutical and Bio-CDMO Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Lonza
- 13.1.1 Lonza Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Lonza Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.1.3 Lonza Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.2 Catalent
- 13.2.1 Catalent Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Catalent Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.2.3 Catalent Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.3 Samsung Biologics
- 13.3.1 Samsung Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Samsung Biologics Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.4 FUJIFILM Diosynth Biotechnologies
- 13.4.1 FUJIFILM Diosynth Biotechnologies Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.5 Boehringer Ingelheim
- 13.5.1 Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.6 WuXi Biologics
- 13.6.1 WuXi Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 WuXi Biologics Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.6.3 WuXi Biologics Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.7 Recipharm
- 13.7.1 Recipharm Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Recipharm Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.7.3 Recipharm Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.8 Thermo Fisher Scientific
- 13.8.1 Thermo Fisher Scientific Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.9 AGC Biologics
- 13.9.1 AGC Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.9.2 AGC Biologics Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.10 Rentschler Biopharma
- 13.10.1 Rentschler Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.10.2 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.11 KBI Biopharma
- 13.11.1 KBI Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.11.2 KBI Biopharma Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.12 Siegfried
- 13.12.1 Siegfried Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.12.2 Siegfried Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.12.3 Siegfried Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.13 Aenova Group
- 13.13.1 Aenova Group Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.13.2 Aenova Group Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.14 GenScript
- 13.14.1 GenScript Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.14.2 GenScript Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.14.3 GenScript Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.15 ProBioGen
- 13.15.1 ProBioGen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.15.2 ProBioGen Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.16 Northway Biotech
- 13.16.1 Northway Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.16.2 Northway Biotech Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.17 3P Biopharmaceuticals
- 13.17.1 3P Biopharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.17.2 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Portfolio
- 13.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Biopharmaceutical and Bio-CDMO Industry Chain Analysis
- 14.2 Biopharmaceutical and Bio-CDMO Industry Raw Material and Suppliers Analysis
- 14.2.1 Biopharmaceutical and Bio-CDMO Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Biopharmaceutical and Bio-CDMO Typical Downstream Customers
- 14.4 Biopharmaceutical and Bio-CDMO Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.